Table 2.
Apoptosis of IM-9, IM-9/Bcl-2 and HepG2 cells treated with jadomycin derivativesa
| Cell lines | % Apoptotic cells |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control |
1 |
2 |
3 |
4 |
5 |
6 |
||||||||
| EAb | NLAc | EA | NLA | EA | NLA | EA | NLA | EA | NLA | EA | NLA | EA | NLA | |
| IM-9 | 3.9 | 3.5 | 25.4 | 36.9 | 13.8 | 11.2 | 16.6 | 11.8 | 22.8 | 15.9 | 29.0 | 19.2 | 15.7 | 14.1 |
| IM-9/Bcl-2 | 2.0 | 2.8 | 7.9 | 4.2 | 3.3 | 2.7 | 6.2 | 2.7 | 11.1 | 3.3 | 19.5 | 6.9 | 8.3 | 4.0 |
| HepG2 | 2.5 | 5.0 | 19.1 | 12.9 | 4.4 | 6.7 | 5.9 | 9.1 | 7.2 | 9.2 | 16.2 | 9.7 | 4.8 | 7.9 |
a
IM-9 and HepG2 were treated with 10 μM of jadomycin derivatives, IM-9/Bcl2 with 20 μM. The percentage of apoptotic cells was determined as average of at least three independent experiments.
b
EA, cells in early stages of apoptosis, annexin-V+/PI−.
c
NLA, cells in necrosis/late apoptosis, annexin-V+/PI+